Booster shot study: can extra vaccine doses keep COVID at bay?

NCT ID NCT04955626

Vaccine Sponsor: BioNTech SE Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This large Phase 3 trial tested whether giving healthy people who already received the Pfizer-BioNTech COVID-19 vaccine one or more extra doses (boosters) is safe and effective. Over 16,000 participants in several countries received either the original vaccine, a version adapted for the Omicron variant, or a placebo. The study looked at how well these boosters prevent COVID-19 infection and tracked side effects like injection site pain and fatigue.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: BNT162b2 (Pfizer-BioNTech COVID-19 vaccine) and variant-adapted versions
What this could lead to: If successful, this study could show that additional doses of the vaccine safely boost protection against COVID-19, including newer variants.
What could go wrong: This is a completed Phase 3 trial, but results may not apply to everyone. Side effects like injection site pain or fatigue are common, and rare serious events are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

16,372 people

The number who actually took part.

Started

Jul 2021

Finished

May 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Substudy A Inclusion Criteria: * Male or female participants ≥16 years of age at Visit 1 (Day 1) who participated in C4591001. * Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures. * Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. * Capable of giving signed informed consent. * Participants who have received 2 prior doses of 30 µg BNT162b2 19-42 days apart, with the second dose being at least 175 days before Visit 1 (Day 1). Exclusion Criteria: * Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention. * Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19. * Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. * Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. * Women who are pregnant or breastfeeding. * Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study. * Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19, from 90 days before study intervention administration, or planned receipt throughout the study. * Prior receipt of any COVID-19 vaccine other than BNT162b2. * Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members. * Receipt of medications intended to prevent COVID-19. * Prior receipt of more than 2 doses of BNT162b2 30 µg. * Participation in other studies involving study intervention within 28 days prior to study entry, other than C4591001, and/or within 28 days of confirmed receipt of BNT162b2 within the study. Substudy B Inclusion Criteria: * Male or female participants 12 to 30 years of age, inclusive, who have received 2 prior doses of 30 µg BNT162b2 19 to 60 days apart, with the second dose being at least at least 4 months (120 days) before Visit 1 (Day 1) * Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures. * Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. * Capable of giving signed informed consent. Exclusion Criteria: * Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behaviour or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention. * Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19. * Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. * Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. * Women who are pregnant or breastfeeding. * Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study. * Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19, from 90 days before study intervention administration, or planned receipt throughout the study. * Prior receipt of any COVID-19 vaccine other than BNT162b2. * Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members. * Receipt of medications intended to prevent COVID-19. * Prior receipt of more than 3 doses of BNT162b2 30 µg. * Participation in other studies involving study intervention within 28 days prior to study entry through and including 28 days after the last dose of study intervention, with the exception of non-Pfizer interventional studies for prevention of COVID-19, which are prohibited throughout study participation. Substudy C Inclusion Criteria: * Male or female participants ≥12 years of age, inclusive, who have received 2 prior doses of 30 µg BNT162b2 19 to 60 days apart, with the second dose being at least 150 days before Visit 301 (Day 1) * Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures. * Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. * Capable of giving signed informed consent. Exclusion Criteria: * Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behaviour or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention. * Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19. * Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. * Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. * Women who are pregnant or breastfeeding. * Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study. * Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19, from 90 days before study intervention administration, or planned receipt throughout the study. * Prior receipt of any COVID-19 vaccine other than BNT162b2. * Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members. * Receipt of medications intended to prevent COVID-19. * Prior receipt of more than 2 doses of BNT162b2 30 µg. * Participation in other studies involving study intervention within 28 days prior to study entry through and including 28 days after the last dose of study intervention, with the exception of non-Pfizer interventional studies for prevention of COVID-19, which are prohibited throughout study participation. Substudy D Inclusion Criteria: * Male or female participants 18 to 55 years of age inclusive * Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures. * Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. * Cohort 2: Participants who provided a serum sample at Visit 3 in Study C4591001, with Visit 3 occurring within the protocol-specified window. * Capable of giving signed informed consent * Cohort 1: Participants who have received 2 prior doses of 30 µg BNT162b2, with the second dose being 90 to 240 days before Visit 401 (Day 1) or Cohort 2: Participants who have received 3 prior doses of 30 µg BNT162b2, with the third dose being 90 to 180 days before Visit 401 (Day 1). Exclusion Criteria: * Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention. * Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19. * Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. * Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. * Women who are pregnant or breastfeeding. * Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study. * Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19, from 90 days before study intervention administration, or planned receipt throughout the study. * Cohorts 1 and 2: prior receipt of any COVID-19 vaccine other than BNT162b2. * Cohort 3 only: prior receipt of any COVID-19 vaccine. * Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members. * Receipt of medications intended to prevent COVID 19. * Participation in other studies involving study intervention within 28 days prior to study entry through and including 28 days after the last dose of study intervention, with the exception of non-Pfizer interventional studies for prevention of COVID-19, which are prohibited throughout study participation. Substudy E Inclusion Criteria: * Groups 1-6: Male or female participants \>55 years of age * Groups 7-9: Male or female participants 18 to 55 years of age * Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures. * Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. * Capable of giving signed informed consent. * Participants who have received 3 prior doses of 30 µg BNT162b2, with the third dose being 5 to 12 months (150 to 360 days) before Visit 601 (Day 1). * Groups 7 to 9 (sentinel participants): Screening troponin levels must be within normal range prior to randomization. Exclusion Criteria: * Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention. * Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19. * Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. * Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. * Women who are pregnant or breastfeeding. * Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study. * Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19, from 90 days before study intervention administration, or planned receipt throughout the study. * Prior receipt of any COVID-19 vaccine other than BNT162b2. * Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members. * Receipt of medications intended to prevent COVID-19. * Participation in other studies involving study intervention within 28 days prior to study entry through and including 28 days after the last dose of study intervention, with the exception of non-Pfizer interventional studies for prevention of COVID-19, which are prohibited throughout study participation. Substudy F Inclusion Criteria: * Male or female participants ≥60 years of age * Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures. * Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. * Capable of giving signed informed consent. * Participants who have received 3 prior doses of 30 µg BNT162b2, with the third dose being ≥4 months before Visit 701 (Day 1). Exclusion Criteria: * Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention. * Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19. * Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. * Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. * Women who are pregnant or breastfeeding. * Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study. * Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19, from 90 days before study intervention administration, or planned receipt throughout the study. * Prior receipt of any COVID-19 vaccine other than BNT162b2. * Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members. * Receipt of medications intended to prevent COVID-19. * Participation in other studies involving study intervention within 28 days prior to study entry through and including 28 days after the last dose of study intervention, with the exception of non-Pfizer interventional studies for prevention of COVID-19, which are prohibited throughout study participation.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 SARS-CoV-2 infection

Contacts and locations

Locations

AMR Clinical

Mobile, Alabama, 36608, United States
AMR Clinical

Newton, Kansas, 67114, United States
AMR Clinical

Wichita, Kansas, 67207, United States
Accel Research Sites - Birmingham Clinical Research Unit

Birmingham, Alabama, 35216, United States
Accellacare

Cary, North Carolina, 27518, United States
Accellacare

Charlotte, North Carolina, 28211, United States
Accellacare

Hickory, North Carolina, 28601, United States
Accellacare

Raleigh, North Carolina, 27609, United States
Accellacare

Wilmington, North Carolina, 28401, United States
Accellacare

Winston-Salem, North Carolina, 27103, United States
Accellacare (formerly PMG Research of Wilmington, LLC)

Wilmington, North Carolina, 28401, United States
Accellacare - Salisbury

Salisbury, North Carolina, 28144, United States
Acevedo Clinical Research Associates

Miami, Florida, 33142, United States
Alliance for Multispecialty Research - Weisgarber Medical Park

Knoxville, Tennessee, 37909, United States
Alliance for Multispecialty Research, LLC

Tempe, Arizona, 85281, United States
Alliance for Multispecialty Research, LLC

Coral Gables, Florida, 33134, United States
Anaheim Clinical Trials, LLC

Anaheim, California, 92801, United States
Bayview Research Group, LLC

Valley Village, California, 91607, United States
Benaroya Research Institute at Virginia Mason

Seattle, Washington, 98101, United States
Benchmark Research

Austin, Texas, 78705, United States
Benchmark Research

Fort Worth, Texas, 76135, United States
Boston Medical Center

Boston, Massachusetts, 02118, United States
Botho Ke Bontle Health Services PTY LTD

Pretoria, Gauteng, 0184, South Africa
Bozeman Health Deaconess Hospital

Bozeman, Montana, 59715, United States
Bozeman Health Deaconess Hospital d/b/a Bozeman Health Clinical Research

Bozeman, Montana, 59715, United States
CEPIC - Centro Paulista de Investigação Clínica

São Paulo, 04266-010, Brazil
California Research Foundation

San Diego, California, 92123, United States
Centricity Research Columbus Ohio Multispecialty

Columbus, Ohio, 43213, United States
Cincinnati Children's Hospital

Cincinnati, Ohio, 45229, United States
Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229, United States
Clinical Alliance for Research & Education - Infectious Diseases (CARE-ID)

Annandale, Virginia, 22003, United States
Clinical Neuroscience Solutions Inc.

Memphis, Tennessee, 38119, United States
Clinical Neuroscience Solutions, Inc.

Orlando, Florida, 32801, United States
Clinical Neuroscience Solutions, Inc. dba CNS Healthcare

Jacksonville, Florida, 32256, United States
Clinical Research Associates Inc

Nashville, Tennessee, 37203, United States
Clinical Research Atlanta

Stockbridge, Georgia, 30281, United States
Clinical Research Consulting

Milford, Connecticut, 06460, United States
Clinical Research Professionals

Chesterfield, Missouri, 63005, United States
Clinical Trials of Texas, Inc.

San Antonio, Texas, 78229, United States
Clinical Trials of Texas, LLC

San Antonio, Texas, 78229, United States
Clinresco Centres

Kempton Park, Gauteng, 1619, South Africa
Collaborative Neuroscience Research, LLC

Long Beach, California, 90806, United States
Collaborative Neuroscience Research, LLC

Los Alamitos, California, 90720, United States
DM Clinical Research

Tomball, Texas, 77375, United States
DM Clinical Research - Bellaire

Houston, Texas, 77081, United States
DM Clinical Research - Kool Kids Pediatrics

Tomball, Texas, 77375, United States
Dayton Clinical Research

Dayton, Ohio, 45406, United States
Dayton Clinical Research

Dayton, Ohio, 45409, United States
Diablo Clinical Research, Inc.

Walnut Creek, California, 94598, United States
Dr A Jacovides & Partners Inc.

Midrand, Gauteng, 1685, South Africa
Duke University - Main Hospital and Clinics

Durham, North Carolina, 27703, United States
East-West Medical Research Institute

Honolulu, Hawaii, 96814, United States
Gallup Indian Medical Center

Gallup, New Mexico, 87301, United States
HG Pediatrics

Houston, Texas, 77008, United States
HOPE Research Institute

Phoenix, Arizona, 85023, United States
Holston Medical Group

Bristol, Tennessee, 37620, United States
Holston Medical Group

Kingsport, Tennessee, 37660, United States
Hope Research Institute

Phoenix, Arizona, 85018, United States
IACT Health

Columbus, Georgia, 31904, United States
IKF Pneumologie GmbH & Co. KG

Frankfurt, 60596, Germany
IMA Clinical Research San Antonio

San Antonio, Texas, 78229, United States
IMA Clinical Research Warren

Warren Township, New Jersey, 07059, United States
Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
Indago Research & Health Center, Inc

Hialeah, Florida, 33012, United States
Innovo Research - Austin Regional Clinic

Austin, Texas, 78726, United States
J. Lewis Research, Inc. / Foothill Family Clinic

Salt Lake City, Utah, 84109, United States
J. Lewis Research, Inc. / Foothill Family Clinic South

Salt Lake City, Utah, 84121, United States
Jacksonville Center for Clinical Research

Jacksonville, Florida, 32216, United States
Johns Hopkins Bayview Medical Center

Baltimore, Maryland, 21224, United States
Johns Hopkins Center for American Indian Health

Chinle, Arizona, 86503, United States
Johns Hopkins Center for American Indian Health

Whiteriver, Arizona, 85941, United States
Johns Hopkins Center for American Indian Health

Gallup, New Mexico, 87301, United States
Johns Hopkins Center for American Indian Health

Shiprock, New Mexico, 87420, United States
Jongaie Research

Pretoria, 0183, South Africa
Kaiser Permanente Center for Health Research

Portland, Oregon, 97227, United States
Kaiser Permanente Los Angeles Medical Center

Los Angeles, California, 90027, United States
Kaiser Permanente Oakland

Oakland, California, 94611, United States
Kaiser Permanente Santa Clara

Santa Clara, California, 95051, United States
Kaiser Permenente Medical Center Infectious Disease

Los Angeles, California, 90027, United States
Kentucky Pediatric/ Adult Research

Bardstown, Kentucky, 40004, United States
Lehigh Valley Health Network/Network Office of Research and Innovation

Allentown, Pennsylvania, 18102, United States
Lillestol Research

Fargo, North Dakota, 58104, United States
Limpopo Clinical Research Initiative

Thabazimbi, Limpopo, 0380, South Africa
LinQ Research, LLC

Pearland, Texas, 77584, United States
Louisiana State University Health Sciences Shreveport

Shreveport, Louisiana, 71101, United States
Lynn Institute of Denver

Aurora, Colorado, 80012, United States
Lynn Institute of Norman

Norman, Oklahoma, 73072, United States
M3 Wake Research, Inc.

Raleigh, North Carolina, 27612, United States
Main Street Physician's Care

Little River, South Carolina, 29566, United States
Medical Affiliated Research Center

Huntsville, Alabama, 35801, United States
Meridian Clinical Research

Savannah, Georgia, 31406, United States
Meridian Clinical Research

Cincinnati, Ohio, 45246, United States
Meridian Clinical Research LLC

Binghamton, New York, 13901, United States
Meridian Clinical Research, LLC

Cincinnati, Ohio, 45219, United States
Methodist Physicians Clinic/CCT Research

Fremont, Nebraska, 68025, United States
Michigan Center of Medical Research (MICHMER)

Farmington Hills, Michigan, 48334, United States
NYU Langone Health

New York, New York, 10016, United States
Newtown Clinical Research

Johannesburg, Gauteng, 2113, South Africa
North Alabama Research Center

Athens, Alabama, 35611, United States
North Texas Infectious Diseases Consultants, P.A

Dallas, Texas, 75246, United States
Northern Navajo Medical Center

Shiprock, New Mexico, 87420, United States
Obras Sociais Irma Dulce

Salvador, Estado de Bahia, 40.415-006, Brazil
Ochsner Clinic Foundation

New Orleans, Louisiana, 70121, United States
Paradigm Clinical Research Centers, Inc

Redding, California, 96001, United States
PharmQuest Life Sciences, LLC

Greensboro, North Carolina, 27408, United States
PriMED Clinical Research

Dayton, Ohio, 45419, United States
Quality Clinical Research

Omaha, Nebraska, 68114, United States
Renu Garg, MD Pediatrics

Houston, Texas, 77008, United States
Research Building

Wenatchee, Washington, 98801, United States
Research Centers of America ( Hollywood )

Hollywood, Florida, 33024, United States
Rochester Clinical Research, Inc.

Rochester, New York, 14609, United States
SCR of Texas, LLC

Keller, Texas, 76248, United States
SMS Clinical Research

Mesquite, Texas, 75149, United States
SUNY Upstate Medical University

Syracuse, New York, 13215, United States
Senders Pediatrics

South Euclid, Ohio, 44121, United States
Sheba Medical Center

Ramat Gan, Central District, 5262100, Israel
Solaris Clinical Research

Meridian, Idaho, 83646, United States
South Jersey Infectious Disease

Somers Point, New Jersey, 08244, United States
Studienzentrum Dr. Keller

Frankfurt, 60389, Germany
Sundance Clinical Research

St Louis, Missouri, 63141, United States
Synergy Biomed Research Institute

East London, Eastern Cape, 5201, South Africa
TREAD Research

Cape Town, Parow, 7500, South Africa
Tekton Research, Inc

Austin, Texas, 78745, United States
The Pain Center of Arizona

Phoenix, Arizona, 85018, United States
Tiervlei Trial Centre

Cape Town, Western Cape, 7530, South Africa
Trinity Clinical Research

Tullahoma, Tennessee, 37388, United States
UC Davis Medical Center

Sacramento, California, 95817, United States
University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106, United States
University of Iowa

Iowa City, Iowa, 52242, United States
University of Massachusetts Chan Medical School

Worcester, Massachusetts, 01655, United States
University of Rochester Medical Center

Rochester, New York, 14642, United States
University of Rochester Medical Center- Kari Steinmetz

Rochester, New York, 14642, United States
VA Northeast Ohio Healthcare System

Cleveland, Ohio, 44106, United States
Van Tran Family Practice

Houston, Texas, 77008, United States
Velocity Clinical Research, Cleveland

Cleveland, Ohio, 44122, United States
Velocity Clinical Research, Covington

Gulfport, Mississippi, 39503, United States
Velocity Clinical Research, Los Angeles

Los Angeles, California, 90057, United States
Velocity Clinical Research, Norfolk

Norfolk, Nebraska, 68701, United States
Velocity Clinical Research, North Hollywood

North Hollywood, California, 91606, United States
Velocity Clinical Research, Omaha

Omaha, Nebraska, 68134, United States
Velocity Clinical Research, Providence

East Greenwich, Rhode Island, 02818, United States
Velocity Clinical Research, Sioux City

Sioux City, Iowa, 51106, United States
Velocity Clinical Research, Vestal

Vestal, New York, 13850, United States
Ventavia Research Group

Fort Worth, Texas, 76104, United States
Ventavia Research Group, LLC

Houston, Texas, 77008, United States
Virginia Research Center

Midlothian, Virginia, 23114, United States
Wake Research - Clinical Research Center of Nevada, LLC

Las Vegas, Nevada, 89106, United States
Wenatchee Valley Hospital

Wenatchee, Washington, 98801, United States
Whiteriver Indian Hospital

Whiteriver, Arizona, 85941, United States
Whiteriver Indian Hospital- Garrett Building

Whiteriver, Arizona, 85941, United States
Worthwhile Clinical Trials

Benoni, Gauteng, 1501, South Africa
Yale Center for Clinical Investigation

New Haven, Connecticut, 06519, United States
Yale University School of Medicine

New Haven, Connecticut, 06510, United States
Yale-New Haven Hospital

New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.